
What is claimed is:

1. A solid form of Compound (**I**)



, characterized by a mean bulk density greater than 0.3 g/cc.

2. The solid form according to claim 1, characterized by a mean tapped density between 0.7 g/cc and 0.9 g/cc.

3. The solid form according to claim 1 or 2, characterized by a Hausner ratio less than or equal to 1.2.

4. The solid form according to any one of claims 1 to 3, characterized by a wet particle size distribution having a D_{10} value greater than 70 µm.

5. The solid form according to any one of claims 1 to 4, characterized by a wet particle size distribution having a D_{50} value greater than 200 µm.

6. The solid form according to any one of claims 1 to 5, characterized by a wet particle size distribution having a D_{90} value greater than 400 µm.

7. The solid form according to any one of claims 1 to 6, characterized by a mass loss of less than 5 wt. % between 20 °C and 240 °C by thermogravimetric analysis.

8. The solid form according to any one of claims 1 to 7, wherein the total level of residual solvents in the solid form is less than 1%.

9. The solid form according to any one of claims 1 to 8, characterized by a glass transition temperature (T_g) greater than 90 °C at 0% relative humidity.


10. The solid form according to any one of claims 1 to 9, wherein:
the residual methanol level is less than 3000 ppm;
the residual isopropyl acetate level is less than 5000 ppm; and/or
the residual heptane level is less than 5000 ppm.

11. The solid form according to any one of claims 1 to 10, wherein:
the residual methanol level is less than 500 ppm;
the residual isopropyl acetate level is less than 4000 ppm; and/or
the residual heptane level is less than 500 ppm.

12. The solid form according to any one of claims 1 to 11, wherein the residual dichloromethane level is less than 1500 ppm.

13. The solid form according to any one of claims 1 to 12, wherein the solid form is substantially amorphous.

14. A solid form of Compound (**I**)



, characterized by a wet particle size distribution having a D_{10} value less than 10 µm.

15. The solid form according to claim 14, characterized by a wet particle size distribution having a D_{10} value between 5 µm and 6 µm or a D_{10} value between 1 and 2 µm.

16. The solid form according to claim 14 or 15, characterized by a wet particle size distribution having a D_{50} value less than 100 µm.

17. The solid form according to any one of claims 14 to 16, characterized by a wet particle size distribution having a D_{90} value less than 200 µm.

18. The solid form according to any one of claims 14 to 17, characterized by a mean bulk density less than 0.3 g/cc.

19. The solid form according to any one of claims 14 to 18, characterized by a mean tapped density less than 0.3 g/cc.

20. The solid form according to any one of claims 14 to 19, characterized by a mass loss of less than 5 wt. % between 20 °C and 240 °C by thermogravimetric analysis.

21. The solid form according to any one of claims 14 to 20, wherein the total level of residual solvents in the solid form is less than 1%.

22. The solid form according to any one of claims 14 to 21, characterized by a glass transition temperature (T_g) greater than 90 °C at 0% relative humidity.

23. The solid form according to any one of claims 14 to 22, wherein:
the residual methanol level is less than 3000 ppm;
the residual isopropyl acetate level is less than 5000 ppm; and/or
the residual heptane level is less than 5000 ppm.

24. The solid form according to any one of claims 14 to 23, wherein:
the residual methanol level is less than 500 ppm;
the residual isopropyl acetate level is less than 4000 ppm; and/or
the residual heptane level is less than 500 ppm.

25. The solid form according to any one of claims 14 to 24, wherein the residual dichloromethane level is less than 1500 ppm.

26. The solid form according to any one of claims 14 to 25, wherein the solid form is substantially amorphous.

27. A pharmaceutical composition comprising:
a solid form of Compound (**I**) according to any one of claims 1 to 26; and
at least one pharmaceutically acceptable excipient.

28. Use of a solid form of Compound (**I**) according to any one of claims 1 to 26 in the manufacture of a medicament for inhibiting Bruton's tyrosine kinase (BTK) in a mammal in need of such BTK inhibition.

29. Use of a solid form of Compound (**I**) according to any one of claims 1 to 26 in the manufacture of a medicament for treating pemphigus vulgaris or pemphigus foliaceus in a mammal in need thereof.

30. Use of a solid form of Compound (I) according to any one of claims 1 to 26 in the manufacture of a medicament for treating immune thrombocytopenia in a mammal in need thereof.